Joseph Paul Eder (Joseph P Eder)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Peritoneal Dialysis

Smoking Cessation

Top Venues

JCO precision oncology

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Yiduo Hu, Azeet Narayan, Yunshan Xu, Julia Wolfe, Dennis Vu, Thi Trinh, Chaitanya Kantak, Susan Percy Ivy, Joseph Paul Eder, Yanhong Deng, Patricia LoRusso, Joseph W Kim, Abhijit A Patel
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO precision oncology 8 (2024)
Yiduo Hu, Azeet Narayan, Yunshan Xu, Julia Wolfe, Dennis Vu, Thi Trinh, Chaitanya Kantak, Susan Percy Ivy, Joseph Paul Eder, Yanhong Deng, Patricia LoRusso, Joseph W Kim, Abhijit A Patel
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO precision oncology 8 (2024)
Yiduo Hu, Azeet Narayan, Yunshan Xu, Julia Wolfe, Dennis Vu, Thi Trinh, Chaitanya Kantak, Susan Percy Ivy, Joseph Paul Eder, Yanhong Deng, Patricia LoRusso, Joseph W Kim, Abhijit A Patel
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO precision oncology 8 (2024)
Yiduo Hu, Azeet Narayan, Yunshan Xu, Julia Wolfe, Dennis Vu, Thi Trinh, Chaitanya Kantak, Susan Percy Ivy, Joseph Paul Eder, Yanhong Deng, Patricia LoRusso, Joseph W Kim, Abhijit A Patel
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO precision oncology 8 (2024)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Joseph Paul Eder, Deborah B Doroshow, Khanh T Do, Vicki L Keedy, Jeffrey S Sklar, Peter M Glazer, Ranjit Bindra, Geoffrey I Shapiro
Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas. JCO precision oncology 5 (2022)
Joseph Paul Eder
Reply to E. Rosenbaum et al. JCO precision oncology 6 (2022)
Haider Mahdi, Navid Hafez, Deborah B Doroshow, Davendra Sohal, Vickie Keedy, Khanh T Do, Patricia LoRusso, Juliane Jürgensmeier, Manuel Avedissian, Jeffrey S Sklar, Colin Glover, Brunella Felicetti, Emma Dean, Peter G S Mortimer, Geoffrey I Shapiro, Joseph Paul Eder
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO precision oncology 5 (2021)